195 Secukinumab Signficantly Improves the Signs and Symptoms of Active Psoriatic Arthritis in Patients Previously Exposed to Anti-Tumour Necrosis Factor Therapy and Anti-Tumour Necrosis Factor-Naive Patients: 52 Week Results from the Phase III Future 2 Trial
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.